Despite improved therapies, some cancers still have 5 year survival rates of less than 20 % (head and neck, pancreas, lungs, etc).
As such, the particularities of each patient’s situation should be assessed when designing treatments to efficiently treat these resistant and deep cancers.
The innovation is an injectable treatment comprised of encapsulated nanoparticles allowing simultaneously treatment through radio and chemotherapy.
Once injected, these particles (followed by MRI) target cancer cells.
Treatment is initiated by radiotherapy when the quantity of nanoparticles revealed by MRI is both large enough in the tumor and low in the surrounding healthy tissues.
The radiation (applied precisely on the nanoparticles) degrades their surrounding capsule, thus releasing the chemotherapeutic agents.
MARKETS AND APPLICATIONS
Treatment and diagnosis of deep, resistant cancers (brain, lungs …)
Technology validated at laboratory scale (TRL 4)
EA 4267 PEPITE (pathologies and epithelia
UTINAM institute, UMR 6213 CNRS UFC
Patent filing : FR 1908368
Co-development to orient the technology according to the needs of manufacturers
Business Developpement Manager
+33 (0)6 26 61 89 06